The shareholder base in Bactiguard is broadened through a transaction comprising 6.6 million shares
The main shareholders in Bactiguard Holding AB (publ) broaden the shareholder base and increase the free float in the company's share through a secondary sale of existing shares to three Swedish institutional owners. The transaction comprises 6.63 million B-shares at the price of SEK 39 per share and the total value amounts to SEK 258.6 million.
"For a period of time we have been working on broadening the institutional ownership in Bactiguard and increasing liquidity in the stock. We have now sold a significant number of shares to three reputable Swedish institutions. Thereby, we have reached our goal and this is positive for the company, us as principal shareholders as well as for the other shareholders in Bactiguard ", says Christian Kinch.
The transaction means that the two principal shareholders Christian Kinch and Thomas von Koch each sell 3,315,000 B shares worth SEK 129.3 million. The total number of shares in the company amounts to 33,302,373 and the total number of votes to 69,302,373. Consequently, the two main shareholders now each own shares corresponding to 18.4 percent of the capital and 34.8 percent of the votes in the company. Together they continue to control the majority of the votes in the company.
Carnegie acted as advisors in the transaction.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2018-09-10, at 08.30
For further information, please contact:
Christian Kinch, CEO
Phone +46 8 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com